BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death

<div><b>Effect of BET-bromodomain inhibition on AML patient samples</b>. BMMCs from four patients were treated with 0.5<i>μ</i>M JQ1 for 48hr and then<i> S100A8</i> and<i> S100A9</i> mRNA levels quantified by qRT-PCR.</div>

Bone Marrow Research

fig5

Figure 5

Figure 5: BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death 

Figure 5 | BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death 